This 1 Sub-$20 Stock Could Beat Tesla?
Learn about the AV tech company that’s quietly raising BILLIONS in Tesla’s shadow… while its stock still trades for under $20 a share.
Get Details HERE.
Francis Patrick Ostronic Insider Alerts

Get notified the next time Francis Patrick Ostronic buys or sells Cyclo Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Francis Patrick Ostronic Insider Information

Director of Cyclo Therapeutics


Mr. Ostronic is an officer of US Pharmacia International, Inc., a subsidiary of USP, and also serves as the Chief Financial Officer of The USP Group. Mr. Ostronic is also a director of Novit US, Inc., the general partner of Novit.

What is Francis Patrick Ostronic's net worth?

The estimated net worth of Francis Patrick Ostronic is at least $303,410.16 as of April 16th, 2021. Mr. Ostronic owns 71,559 shares of Cyclo Therapeutics stock worth more than $303,410 as of January 17th. This net worth evaluation does not reflect any other assets that Mr. Ostronic may own. Learn More.

How do I contact Francis Patrick Ostronic?

The corporate mailing address for Mr. Ostronic and other Cyclo Therapeutics executives is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. Cyclo Therapeutics can also be reached via phone at (386) 418-8060 and via email at [email protected]

Has Francis Patrick Ostronic been buying or selling shares of Cyclo Therapeutics?

During the last quarter, Francis Patrick Ostronic has bought $8,548.00 in Cyclo Therapeutics stock. Most recently, on Friday, January 14th, Francis Patrick Ostronic bought 2,137 shares of Cyclo Therapeutics stock. The stock was acquired at an average cost of $4.00 per share, with a total value of $8,548.00.

Who are Cyclo Therapeutics' active insiders?

Cyclo Therapeutics' insider roster includes Joshua Fine (CFO), N. Fine (CEO), Sharon Hrynkow (Insider), Francis Ostronic (Director), Markus Sieger (Director), and Jeffrey Tate (COO).

Are insiders buying or selling shares of Cyclo Therapeutics?

During the last twelve months, Cyclo Therapeutics insiders bought shares 19 times. They purchased a total of 85,502 shares worth more than $535,328.70. The most recent insider tranaction occured on January, 14th when Director Francis Patrick Ostronic bought 2,137 shares worth more than $8,548.00. Insiders at Cyclo Therapeutics own 12.3 % of the company.

Information on this page was last updated on 1/14/2022.

Francis Patrick Ostronic Insider Trading History at Cyclo Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/14/2022Buy2,137$4.00$8,548.00View SEC Filing Icon  
12/15/2021Buy3,000$3.90$11,700.00View SEC Filing Icon  
12/3/2021Buy864$4.75$4,104.00View SEC Filing Icon  
12/1/2021Buy5,000$5.00$25,000.00View SEC Filing Icon  
11/19/2021Buy10,652$5.25$55,923.00View SEC Filing Icon  
10/29/2021Buy1,000$5.90$5,900.00View SEC Filing Icon  
4/16/2021Buy10,000$6.53$65,300.0071,559View SEC Filing Icon  
4/12/2021Buy5,000$7.00$35,000.00
12/17/2020Buy30,000$4.66$139,800.00
See Full Table

Francis Patrick Ostronic Buying and Selling Activity at Cyclo Therapeutics

This chart shows Francis Patrick Ostronic's buying and selling at Cyclo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclo Therapeutics Company Overview

Cyclo Therapeutics logo
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
Read More

Today's Range

Now: $4.24
Low: $4.00
High: $4.50

50 Day Range

MA: $4.82
Low: $3.47
High: $7.34

2 Week Range

Now: $4.24
Low: $3.43
High: $17.75

Volume

139,510 shs

Average Volume

130,190 shs

Market Capitalization

$27.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
This 1 Sub-$20 Stock Could Beat Tesla?
Learn about the AV tech company that’s quietly raising BILLIONS in Tesla’s shadow… while its stock still trades for under $20 a share.
Get Details HERE.